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ABSTRACT 
Effects of hypercholesterolemia on alterations of serum proteins have not been fully elucidated. Herein, using 
two-dimensional gel electrophoresis (2-DE) in conjunction with LC-MS searching has successfully been carried 
out to investigate the change of protein expression profiles as consequences of raised blood cholesterol at differ-
ent levels (normal group: total cholesterol  200 mg/dL; borderline high group: total cholesterol 200-239 mg/dL; 
and high group: total cholesterol ≥ 240 mg/dL) (n = 45). Results revealed that down-regulation of retinol-binding 
protein 4 (RBP4) (-2.26 fold), transthyretin (-1.25 fold) and gelsolin (-1.47 fold) was observed in the high group. 
Meanwhile, the other proteins such as haptoglobin, complement factor B and CD5 antigen-like protein were up-
regulated upto +3.24, +1.96 and +2.04 fold, respectively. Confirmation by Western blotting revealed a signifi-
cant reduction of RBP4 (approximately 50 %) in individual samples derived from the high group. Presumptive 
conclusion can be drawn that down-regulation of RBP4 might be attributable to the inflammation of adipocytes 
caused by the release of proinflammatory cytokines (e.g. tumor necrosis factor α and interleukin-1β) from adi-
pose tissues. Moreover, the decrease of transthyretin might also be taken into accounts since it is known that the 
transthyretin usually forms complex with RBP4 to prevent glomerular filtration and excretion through the kid-
ney. The suppressing effect on RBP4 should be potentiated by the increase of complement factor B and CD5 an-
tigen-like protein, which rendered the adipose tissues to overwhelm the liberation of RBP4 to blood circulation 
by metabolic and inflammatory processes. Such inflammation could further modulate the induction of cytokine 
release (e.g. IL-6 and IL-1β), resulting in the synthesis of acute phase protein, in particular, haptoglobin and C-
reactive proteins from hepatocytes. However, the mechanism of gelsolin reduction remains unclear. Among 
these differentially expressed proteins, the RBP4 has been proposed as a major linkage between hypercholester-
olemia, adipose tissues, liver and kidney, which is believed to be a potential biomarker for metabolic and cardio-
vascular disorders associated with dyslipidemia in the future. 
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INTRODUCTION 
Hypercholesterolemia, defined as high 
cholesterol levels in the blood, is one of the 
major risk factors for development and pro-
gression of artherosclerosis, cardiovascular 
diseases and stroke (Aguilar and Fernandez, 
2014; Cui et al., 2012; Tracy and Tracy, 
1997). The causes of hypercholesterolemia 
are associated with increased age, over-
weight, smoking, alcohol consumption, and 
family history (Cui et al., 2012; Le et al., 
2006). Data from World Health Organization 
(WHO, 2015) showed that mean value of 
blood cholesterol in Thailand of both gen-
ders was in a high range (5.1-5.6 mmol/L or 
196.91-216.22 mg/dL) and prevalence of 
raised blood cholesterol was in between 
50.0-59.9 % (WHO, 2015). Although, the 
hypercholesterolemia is asymptomatic, ele-
vation of blood cholesterol for a long time 
leads to artherosclerosis and other pathologi-
cal conditions. These include induction of 
oxidative stress at the blood-brain barrier 
(Dias et al., 2014), induction of angiogenesis 
and breast tumors (Pelton et al., 2014), in-
duction of adipose dysfunction (Aguilar and 
Fernandez, 2014), accumulation of choles-
terol in macrophages and other immune cells 
(Tall and Yvan-Charvet, 2015). However, 
the underlying mechanisms of such conse-
quences remain not fully understood. 
Proteomics approach is very useful and 
powerful technology for detection and iden-
tification of protein expression in cells and 
biological samples (for recent review please 
see Larance and Lamond, 2015; Zhang et al., 
2013). Such expression can be detected even 
under normal condition or disease progres-
sion. Therefore, proteomics has extensively 
been applied not only to discover new bi-
omarker but also to gain more understanding 
on the underlying mechanism of several dis-
eases e.g. diabetes, cancer, alzeimer’s dis-
ease and cardiovascular diseases (Ge and 
Wang, 2012; Sallam, 2015; Scott et al., 
2005; Zurbig and Jahn, 2012). For the latter, 
proteomics profilings of cardiovascular dis-
eases and their related disorders have been 
studied for more than a decade. For circum-
stances, changes of distribution of transthy-
retin (TTR) forms in serum of acute myocar-
dial infarction (AMI) have been detected 
(Cubedo et al., 2012). Moreover, differential 
expression of retinol-binding protein 4 
(RBP4) has been observed in acute new-
onset AMI patients and in high-risk patients 
with heterozygous familial hypercholesterol-
emia (FH) (Cubedo et al., 2014). Potential 
protein markers e.g. haptoglobin and serum 
amyloid A have been discovered for athero-
thrombotic ischemic stroke diagnosis (Brea 
et al., 2009). In-depth molecular mechanism 
of protein alterations after simvastatin treat-
ment was investigated in moderate hyper-
cholesterolemic patients (Alonso-Orgaz et 
al., 2006). However, notification has to be 
made that most of the studies were conduct-
ed at the disease states or after treatment. As 
a matter of fact, detection of abnormalities as 
early as possible prior to disease develop-
ment and progression is particularly im-
portant for health prevention and promotion. 
Therefore, the present study aims at investi-
gating the molecular mechanism and asso-
ciation between different levels of blood 
cholesterol and human serum proteins by 
proteomics and seeking for potential protein 
target that will be applied as early bi-
omarkers for clinical diagnosis in the future. 
 
MATERIALS AND METHODS 
Sample collection 
Blood samples were collected as left-
over specimens from Center of Medical La-
boratory Services, Faculty of Medical Tech-
nology, Mahidol University. Based on the 
guidelines from the 2013 National Choles-
terol Education Program Adult Treatment 
Panel (NCEP:ATP III), the criteria for selec-
tion of blood samples in this study are as fol-
lows: Group I normal blood parameters (total 
cholesterol  200 mg/dL; n = 15); Group II 
blood samples with borderline high of total 
cholesterol (total cholesterol 200-239 mg/dL; 
n = 15); Group III blood samples with high 
total cholesterol (total cholesterol ≥ 240 
mg/dL; n = 15). Other blood parameters 
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Table 1: Characteristics and blood parameters of the studied group 
Group 
Parameters Normal Borderline high High 
Age (years) 60.47 ± 10.86 64.27 ± 12.80 52.33 ± 15.21 
Male/female 3/12 6/9 6/9 
Total cholesterol (mg/dL) 183.33 ± 11.67 220.60 ± 10.03 265.33 ± 21.76 
LDL-cholesterol (mg/dL) 104.67 ± 11.97 129.34 ± 16.59 178.23 ± 22.84 
HDL-cholesterol (mg/dL) 55.12 ± 8.87 63.61 ± 16.55 61.94 ± 16.28 
Triglyceride (mg/dL) 120.73 ± 33.27 138.27 ± 49.8 125.80 ± 55.09 
Glucose (mg/dL) 82.60 ± 8.76 91.40 ± 9.71 81.00 ± 15.28 
AST (U/L) 22.33 ± 7.57 17.5 ± 2.12 24.00 ± 2.23 
ALP (U/L) 20.75 ± 8.42 19.50 ± 4.95 25.50 ± 11.50 
BUN (mg/dL) 15 ± 2.64 16.50 ± 0.70 14.00 ± 1.00 
Creatinine (mg/dL) 0.72 ± 0.32 0.99 ± 0.16 0.84 ± 0.17 
 
were in the normal ranges (Table 1). Serum 
samples were prepared from venous blood 
and centrifuged at 2,500 g for 15 min. Then, 
serum samples were placed into microtubes 
and stored at −80 °C until used. 
 
Proteomics study 
Sample preparation 
Pooled serum samples were generated (3 
 5 samples; total = 15 samples per group). 
To improve the performance of proteomics 
analysis, high abundant proteins in the serum 
sample (e.g. albumin and immunoglobulin) 
were removed by using ProteoPrep Immu-
noaffinity Albumin and IgG Depletion Kit 
(Sigma Aldrich, USA) in accordance with 
the manufacturer’s instructions. The depleted 
serum samples were subsequently precipitat-
ed by using 2-D Clean-up kit (GE 
Healthcare, USA). Then, the protein pellets 
were dissolved in sample buffer containing 
7 M urea, 2 M thiourea, 4 % CHAPS; freshly 
prepared by supplementation with 10 mg/ml 
dithiothreitol (DTT) and 10 µl/ml protease 
inhibitor cocktail. 
 
Determination of protein concentration 
The protein concentration was measured 
by the Bradford’s method. The known con-
centrations (2-10 mg/ml) of bovine serum 
albumin (BSA) were applied for protein 
standard curve. Briefly, 800 µl of protein so-
lution (798 µl of deionized water and 2 µl of 
depleted serum protein in lysis buffer) react-
ed with 200 µl of Bradford solution (Bio-
Rad Laboratory, USA). The mixture of pro-
tein solution was incubated at room tempera-
ture for 10 min before determining the opti-
cal density at wavelength of 596 nm. 
 
Two-Dimensional Gel Electrophoresis  
(2-DE) 
Two-dimensional gel electrophoresis was 
carried out using 2-D Electrophoresis Sys-
tem (GE Healthcare, USA) as described pre-
viously (Isarankura-Na-Ayudhya et al., 
2010) with some modification. One hundred 
twenty micrograms of protein sample was 
mixed with 340 μl of rehydration buffer 
(8 M urea, 4 % CHAPS, 2 mM TBP, 
0.001 % bromphenol blue and 65 mM dithio-
threitol) containing 1 % 3-10 NL IPG buffer. 
The mixture was loaded onto 18-cm IPG 
strips with pH range of 3-10 non-linear of an 
isoelectric focusing system (IPGphoreTM). 
Samples were run through steps of strip re-
hydration (20 °C, 12 h) and isoelectric focus-
ing (500 volts for 1 h, 1,000 volts for 1 h, 
and 8,000 volts to reach 33,000 volt·h). 
The maximum current was maintained at 
50 mA per one strip. After the complete pro-
cess was accomplished, the strip was equili-
brated twice times (15 min each) in equili-
bration buffer (50 mM Tris pH 8.8, 6 M 
urea, 30 % glycerol, 2 % SDS, 0.03 % 
bromphenol blue) supplemented with 65 mM 
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DTT and 135 mM iodoacetamide to allow 
the cysteine residues to be reduced and then 
carbamidomethylated. The strip was subject-
ed to the second dimensional separation 
(HoeferTM DALT) using a SDS-polyacryl-
amide gel (12.5 %). Separation of protein 
was executed under the applied voltage of 10 
volt per gel at 20 °C until the bromphenol 
blue dye front reached 0.5 cm from the bot-
tom of the gel. 
 
Gel staining 
The gels were stained with colloidal 
Coomassie blue staining according to the 
standard recommendation. Briefly, 2-DE 
gels were agitated for overnight with Coo-
massie blue. The gels were then destained 
with milli-Q water until a clear background 
was observed. 
 
Differential protein expression analysis 
After staining, gel images were acquired 
using Image scanner III (GE Healthcare, 
USA). Differential analysis was performed 
by ImageMaster 2D Platinum version 7.0 
(GE Healthcare, USA) software tool. These 
included spot intensity calibration, spot de-
tection and background subtraction. Quanti-
fication of intensity of each spot was per-
formed in term of spot volume (area  inten-
sity). The total spot volume normalization 
method was applied in which the percentage 
of each spot volume on a gel image is calcu-
lated relatively to the total volume of all 
spots on that image. Then, determination of 
differentially expressed proteins was con-
ducted by comparing the ratio of % volume 
values with control. After complete analysis, 
these gels were kept at 4 °C until protein 
identification. 
 
In-gel trypsin digestion for protein  
identification 
For identification of protein spots, pro-
teins were cleaved by using in-gel trypsin 
digestion procedure. First, the protein spots 
were excised from 2-DE gel and washed 
twice times with 100 µl of 50 % acetonitrile 
(ACN)/25 mM ammonium bicarbonate 
(NH4HCO3) at room temperature for 15 min. 
Then, the solvent was removed and 50- 
100 µl of 100 % acetonitrile was added for 
10 min or until all gels were in white. After 
that, the acetonitrile was removed and 10- 
15 µl of diluted trypsin (diluted 0.1 mg/mL 
stock trypsin 1:10 into 25 mM ammonium 
bicarbonate) was added into each tube at 
37 °C for 16-24 hrs. Next, the supernatants 
were removed to new tubes. Peptide were 
extracted twice times by adding 15-25 µl of 
50 % acetonitrile, 5 % trifluoroacetic acid 
(TFA) to each tube containing gel slice for 
15 min. Then, the extracted peptides were 
removed and combined with the supernatant 
in new tubes. Finally, the extracted peptides 
were dried in a vacuum centrifuge to dryness 
prior to further experiments. 
 
Peptide identification by ESI-Ion trap-Mass 
spectrometry 
Peptides were reconstituted in 10 µl of 
0.1 % formic acid (FA) and identified by 
liquid chromatography-mass spectrometry 
(LC-MS/MS) consisting of a liquid chroma-
tography part (Dionex Ultimate 3000, Ther-
mo Scientific, USA) in combination with an 
electrospray ionization (ESI)/ion trap mass 
spectrometer (Model amazon SL, Bruker, 
Germany). The LC separation was per-
formed on a reversed phase column 
(Hypersil GOLD 50 × 0.5 mm, 5 μm C18), 
protected by a guard column (Hypersil 
GOLD 30 × 0.5 mm, 5 μm C18), eluted at a 
flow rate of 100 μl/min under gradient condi-
tions of 5-80 % B over 50 min. Mobile phase 
A consists of water/formic acid (99.9:0.1, 
v/v), and B consists of acetonitrile (100, v/v). 
Mass spectral data from 300 to 1500 m/z was 
collected in the positive ionization mode. 
 
Database searching for protein identifi-
cation 
To identify protein, all MS/MS spectra 
recorded on tryptic peptides derived from 
each spot were searched against protein se-
quences from NCBInr and SwissProt data-
bases using the MASCOT search program 
(www.matrixscience.com). 
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Western blotting 
Expression of retinol-binding protein 4 
was confirmed by Western blotting. In detail, 
10 µg of serum protein (15 individual serum 
samples) were separated by 12 % (w/v) 
SDS-PAGE, and then blotted onto a nitrocel-
lulose membrane. The blotting was per-
formed for 1.5 hrs at 110 Volts. After blot-
ting, the membrane was stained with Pon-
ceau S to visualize the position of protein. 
Then, the membrane was removed Ponceau 
S and washed three times by mixture of Tris-
buffered saline and Tween 20 (TBST) buffer 
for 5 min at room temperature. The mem-
brane was soaked with blocking solution 
(5 % w/v non fat milk in TBST buffer) for 
1 h at room temperature. The membrane was 
washed three times for 5 min in TBST buffer 
and incubated at 4 °C for overnight with 
1:2000 dilution of anti-RBP4 antibody 
(Thermofisher Scientific, USA) in TBS buff-
er, and then washed three times for 5 min 
with TBST buffer. And, the membrane was 
incubated at room temperature for 2 hrs with 
a 1:10000 dilution of horseradish peroxidase 
conjugated goat anti-mouse IgG secondary 
antibody in TBS buffer. Excess antibody was 
washed three times for 5 min with TBST 
buffer before detection. The positive band 
was detected using an enhanced chemilumi-
nescence (ECL) system. After immunodetec-
tion, the membranes were stained with Coo-
massie Blue as internal control for normaliza-
tion. Differential proteins were analyzed by 
ImageQuant TL software (GE Healthcare, 
USA). 
 
Statistical analysis 
All data are expressd as mean ± standard 
deviation (SD). For group comparisons, data 
were determined by Analysis of variance 
(ANOVA). The strength of each association 
is presented as the regression coefficient 
with 95 % confidence interval and P-value. 
A P-value < 0.05 was considered statistically 
significant. 
 
RESULTS 
Lipid parameters among groups of study 
As shown in Table 1, the mean values of 
total blood cholesterol were of 183, 220 and 
265 mg/dL for the normal, borderline high 
and high groups, respectively. Notification 
has to be made that the levels of LDL-
cholesterol in all samples of the high group 
exceeded that of the reference value (< 130 
mg/dL) while some of the borderline high 
group remained in the normal range. On av-
erage, the levels of HDL-cholesterol in all 
samples were in the acceptable range (> 40 
mg/dL). A wide distribution was found only 
on the triglyceride content in each group 
since the normal value should be less than 
150 mg/dL. Other parameters were in the 
normal ranges. 
 
Master map of normal human serum 
Figure 1 illustrates a master map of pro-
tein expression profile of human serum after 
removal of high abundant proteins (e.g. al-
bumin and immunoglobulin). Approxi-
mately 250 spots of protein were found on 
18-cm 2-DE gel (with pH 3-10 non-linear 
gradient) stained with colloidal Coomassie 
blue. These proteins were further digested by 
trypsin and identified by electrospray ioniza-
tion-Ion trap-mass spectrometry (ESI-Ion 
trap-MS) and the results were summarised in 
Table 2. 
 
Comparative analysis of protein expression 
profiles in association with different levels 
of total cholesterol 
In comparative analysis, the total spots of 
protein were observed as 260 ± 13.08 spots, 
243 ± 8.33 spots and 237 ± 8.89 spots in 
normal, borderline high and high groups, re-
spectively (Figure 2). The proteomics pro-
files of serum in borderline high and high 
groups resembled those of the normal group. 
However, 6 groups of proteins (located in 
boxes) including retinol-binding protein 4 
(spot no. 27 in Figure 1 and Table 2), trans-
thyretin (spot no. 21), gelsolin (spot no. 7), 
haptoglobin α 1 chain (absence in normal 
group), complement factor B (spot no. 8), 
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Figure 1: A master map of of human serum (after depletion of high abundance proteins) by 2-DE and 
Coomassie blue staining 
 
CD5 antigen-like protein (spot no. 11) were 
differentially expressed. In zoomed gels, it is 
noteworthy that the retinol-binding protein 4 
exists as two spots at the same pI (~5.7) with 
differences in molecular weight (designated 
as spots 1 and 2 for the higher and lower mo-
lecular weight, respectively) (Figure 3). The 
presence of these two isoforms was in con-
sistency with previous studies (Cubedo, Pa-
dro, Cinca, Mata, Alonso and Badimon, 
2014). From our findings, three proteins 
(spot 2 of RBP4, transthyretin and gelsolin) 
were down-regulated while the others (spot 1 
of RBP4, haptoglobin α 1 chain, complement 
factor B and CD5 antigen-like protein) were 
up-regulated when compared with those 
found in the normal group. 
In quantitative study, the mean values of 
protein expression (represented in fold 
changes) from the pooled serum (3  5 sam-
ples; total = 15 samples per group) were ex-
tracted from 9 gels (3 independent experi-
ments) (Table 3). Our findings revealed that 
the spot 2 of RBP4 was down-regulated upto 
-2.26 fold in the high cholesterol group while 
a lesser extent was detected in the borderline 
high group (-1.32 fold). The expression level 
of transthyretin was also reduced in border-
line high group (-1.11 fold) and high group 
(-1.25 fold) when compared with the normal 
group. For the gelsolin, it was found that 
there were 2 isoforms separated by pI. Both 
isoforms were found to be decreased, partic-
ularly in the high group (1.36-1.47 fold). The 
expression level of complement factor B was 
higher in the borderline high group (+1.53 
fold) and high group (+1.96 fold) than the 
normal group. Similar observation was also 
taken in the case of CD5 antigen-like protein 
(+1.83 fold and +2.04 fold in borderline high 
and high groups, respectively). Interestingly, 
the haptoglobin α1 chain was not detected in 
the normal group while high expression of 
protein (upto +3.24 fold) was observed in a 
concentration dependent manner with the 
level of cholesterol. 
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Table 2: Peptide mass fingerprinting of human serum after depletion of high abundance proteins  
identified by ESI-Ion trap mass spectrometry 
Spot  
area No. Protein Identification 
Mw 
(Da) pI Score 
Individual 
ions 
scores 
Sequence 
coverage
1 Alpha-1B-glycoprotein 54220 5.56 271 > 35 14 % 
2 Hemopexin 52385 6.55 446 > 34 28 % 
3 Alpha-1-antichymotrypsin 47792 5.33 59 > 35 4 % 
4 Alpha-2-HS-glycoprotein 40098 5.43 64 > 35 11 % 
5 Alpha-1-antitrypsin 46878 5.37 1033 > 34 68 % 
6 Vitamin D-binding protein 54526 5.40 280 > 35 14 % 
7 Gelsolin 86043 5.90 188 > 35 7 % 
8 Complement factor B 86847 6.67 201 > 35 8 % 
9 Complement C3 188569 6.02 828 > 35 11 % 
10 Haptoglobin 45861 6.13 611 > 35 33 % 
11 CD5 antigen-like protein 39603 5.28 247 > 35 22 % 
12 Plasminogen 93247 7.04 208 > 35 9 % 
13 Complement factor B 86847 6.67 218 > 35 7 % 
14 Beta-2-glycoprotein 39584 8.34 89 > 35 4 % 
15 Complement component C8 beta chain 67003 8.50 42 > 35 5 % 
16 Alpha-2-macroglobulin 164613 6.03 98 > 35 2 % 
17 Complement C4-A 194261 6.65 23 > 35 1 % 
18 Serum amyloid P-component 25485 6.10 67 > 35 27 % 
19 Alpha-1-acid glycoprotein 1 23725 4.93 44 > 35 12 % 
20 Haptoglobin 45861 6.13 99 > 34 16 % 
21 Transthyretin 15991 5.52 245 > 34 59 % 
22 Ig gamma-2 chain C region 36505 7.66 35 > 35 4 % 
23 Alpha-1-antichymotrypsin 47792 5.33 41 > 35 21 % 
24 Antithrombin-III 53025 6.32 40 > 35 11 % 
25 Alpha-2-macroglobulin 164613 6.03 64 > 35 4 % 
26 Complement C4-A 194261 6.65 86 > 34 4 % 
27 Retinol-binding protein 4 23337 5.76 41 > 35 24 % 
28 Haptoglobin-related protein 39518 6.63 53 > 35 6 % 
29 Serotransferrin 79294 6.81 743 > 33 58 % 
30 Complement C3 188569 6.02 363 > 35 11 % 
31 Complement C4-A 194261 6.65 282 > 35 4 % 
32 Complement C3 188569 6.02 48 > 35 3 % 
33 Ig kappa chain V-III region 11882 8.70 65 > 35 20 % 
34 Ig kappa chain C region 11773 5.58 35 > 35 34 % 
35 Ig kappa chain V-III region 11882 8.70 47 > 35 14 % 
36 Immunoglobulin J chain 18543 5.12 54 > 35 23 % 
37 Ig alpha-1 chain C region 38486 6.08 53 > 35 10 % 
38 Ig alpha-2 chain C region 37301 5.71 45 > 35 6 % 
39 Complement C3 188569 6.02 57 > 35 2 % 
Note: Protein scores greater than 35 are significant (p < 0.05). Protein scores and sequences coverage of multiple protein spots 
were given. 
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Figure 2: Comparison of 2-DE gels of human serum from normal (a), borderline high (b), and high to-
tal cholesterol (c) groups 
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Figure 3: Down- and up-regulation of the changed proteins (a-f) found in normal, borderline high, and 
high total cholesterol groups 
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Table 3: Changes of differentially expressed proteins of borderline high and high groups 
compared with normal group 
Protein 
Up(+) / Down(-) regulation (fold) 
Normal Borderline high High 
Retinol-binding protein 4 (Spot 2) 1.00 -1.32 -2.26 
Transthyretin 1.00 -1.11 -1.25 
Gelsolin (Spot 1) 1.00 -0.98 -1.47 
Gelsolin (Spot 2) 1.00 -0.97 -1.36 
Haptoglobin 1 chain Not detected 1.00 +3.24 
Complement factor B 1.00 +1.53 +1.96 
CD5 antigen-like protein 1.00 +1.83 +2.04 
 
 
Western blotting analysis of RBP4 
To further confirm the expression level 
of retinol-binding protein 4 found in 2-DE, 
Western blotting was carried out on individ-
ual samples (n = 15). As shown in Figure 4b, 
the bands of RBP4 located around 23 kDa in 
each lane. Results from the band intensity 
analysis (Figure 4b) indicated that the ex-
pression of RBP4 in the borderline high and 
high groups were of approximately 30 % and 
50 % lower than that of the normal group, 
which were in good agreement with those 
observed on the 2-DE gels (Figure 4a). 
 
DISCUSSION 
Herein, proteomics approach has suc-
cessfully been applied to investigate the dif-
ferential expression of serum protein under 
different levels of hypercholesterolemia. Re-
sults revealed that six protein spots from 
two-dimensional gel electrophoresis (2-DE) 
showed different expression levels in ac-
cordance with the levels of total cholesterol 
(Figures 2 and 3). After protein identification 
by ESI-Ion trap-MS (Table 2), the function 
of these six proteins involved in lipid metab-
olism, inflammation, and immune responses. 
Three proteins, retinol-binding protein 4 
(RBP4), transthyretin (TTR) and gelsolin, 
were lower in borderline high and high 
groups than that of the normal group (Figure 
3a-c, Table 3). While, expression of hapto-
globin, complement factor B (CFB) and CD5 
antigen-like protein (CD5L) were higher in 
borderline high and high groups than that of  
 
Figure 4: Determination of spot intensity of 
RBP4 by 2-DE (a) and Western blotting (b) in 
normal, borderline high, and high total cholester-
ol groups 
 
the normal group (Figure 3d-f, Table 3). 
Plausible mechanisms of alterations of these 
serum proteins as consequences of hypercho-
lesterolemia have been schematically depict-
ed in Figure 5 and summarised as follows. 
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Figure 5: Plausible association of hypercholesterolemia and other human serum proteins and their 
roles in adipose tissues, liver, kidney and blood circulation 
 
First, our results revealed that the levels 
of RBP4 (spot 2) expression were negatively 
correlated with levels of blood cholesterol 
(Table 3 and Figure 4). RBP4 is one of adi-
pocytokines (synthesized from liver and adi-
pose tissues) that delivers a retinol (vitamin 
A) from the liver into the tissue (Kotnik et 
al., 2011). A decrease of RBP4 as a conse-
quence of hypercholesterolemia might be at-
tributable to the inflammation of adipose tis-
sues. Previous studies suggested that adipose 
tissue is a major site of cholesterol metabo-
lism. The existence of hypercholesterolemia 
is documented to induce adipocyte choles-
terol overload and inflammation (Aguilar 
and Fernandez, 2014). Such inflammation 
consequently led to the release of proin-
flammatory cytokines (e.g. tumor necrosis 
factor α (TNF-α) and interleukin-1β (IL-1β) 
from adipose tissues) (Coppack, 2001; 
Zoccali et al., 2003). In parallel, it is also re-
ported that hypercholesterolemia and high 
cholesterol diet could increase the produc-
tion of TNF-α and IL-1β, resulting in the 
amplification of inflammatory process 
(Kotnik et al., 2013; Sell and Eckel, 2007; 
Yoon et al., 2013). 
Supportive evidences can be drawn that 
hypercholesterolemia can increase the inci-
dence of stroke and ischemic heart disease 
(IHD) as the effects of these proinflammato-
ry cytokines (Cui et al., 2012; Saito et al., 
1996; Zhan et al., 2014). Accumulation of 
these proinflammatory cytokines further 
suppresses the release of RBP4 from adipose 
tissues into the blood circulation (Kotnik et 
al., 2013; Sell and Eckel, 2007). On one 
hand, it can be suggested that the level of 
RBP4 in the bloodstream was decreased by 
these proinflammatory cytokines. On the 
other hand, the decrease of serum RBP4 
could also be affected by the inflammation 
of liver and the loss of RBP4 through the 
kidney. Our results revealed that the trans-
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thyretin (TTR) or prealbumin related with 
the levels of RBP4 (Figure 3 and Table 3). 
TTR is a transport protein involved in the 
blood transport of different molecules with 
high binding capacity for thyroxine (T4), tri-
iodothyronine (T3) and holo-retinol-binding 
protein. In the blood circulation, RBP4 forms 
a complex with TTR, which increases the 
molecular mass of RBP4 to prevent glomeru-
lar filtration and excretion through the kid-
ney (Cubedo et al., 2012). These evidences 
lend support to the decrease of RBP4 and 
TTR in human serum associated with hyper-
cholesterolemia. The reduction of RBP4 in 
the blood circulation was also found in other 
pathological conditions such as acute myo-
cardial infarction, ischemic heart disease, 
cholesterol gallstones, stroke, liver disease, 
and type I diabetes (Bahr et al., 2009; 
Cubedo et al., 2014; Pullakhandam et al., 
2012; Wang et al., 2010). 
Second, up-regulation of CD5 antigen-
like protein (CD5L) and complement factor 
B (CFB) (approximately 2 fold) was found 
in the high group (Table 3). CD5L or apop-
tosis inhibitor of macrophage (AIM) is se-
creted by macrophages and has been shown 
to promote macrophage survival (Arai et al., 
2005). In this study, expression levels of 
CD5L in borderline high and high groups 
were higher than that of the normal group. 
This result is in a good agreement with other 
studies that found high expression of serum 
AIM in mice fed with high fat diet and AIM 
induction is involved in atherosclerogenesis 
by supporting the survival of macrophages 
within the lesions (Arai et al., 2005; Kuro-
kawa et al., 2010). Blood AIM is incorpo-
rated into adipocytes via endocytosis medi-
ated by CD36. Then, AIM induces lipolysis 
in adipocytes and suppresses increased fat 
mass. After that, saturated fatty acid is ef-
fluxed from adipocytes as a result of lipoly-
sis. The increased fatty acid residues subse-
quently activated chemokine production in 
adipocytes via the stimulation of toll-like re-
ceptor 4 (TLR4). After chemokine induction, 
M1 macrophages are recruited into the adi-
pose tissue by macrophage infiltration (Arai 
and Miyazaki, 2014; Miyazaki et al., 2011), 
resulting in the production of proinflamma-
tory cytokines (TNF-α and IL-1β). This phe-
nomenon was also potentiated by the in-
creased expression of CFB. The CFB is cen-
trally component of the alternative comple-
ment pathway. A cascade of alternative 
pathway activation consists of complement 
C3, CFB, and complement factor D. Previ-
ous studies have found that adipose tissues 
are the main source of these complements 
(Brocca et al., 2013; Zhang et al., 2007). 
They can produce acylation-stimulating pro-
tein (ASP) that is a stimulator of triglyceride 
synthesis and glucose transport in adipocyte 
and fibroblast cells. Furthermore, the com-
plement system plays role in the initiation 
and maintainance of inflammation (Cian-
flone et al., 2003; Zhang et al., 2007). Taken 
together, the increases of CD5L and CFB 
rendered the adipose tissues to suppress the 
release of RBP4 by metabolic and inflamma-
tory processes. 
Third, expression of gelsolin and hapto-
globin was in the opposite manner (-1.47 and 
+3.24 fold, respectively). Gelsolin is an in-
tracellular actin-binding protein that in-
volved in changes of cell shape, cell motility, 
and apoptosis. Gelsolin is produced by mus-
cle that is an abundant protein of extracellu-
lar fluids capable of serving actin filaments 
and eliminating actin from the circulation 
(Yu et al., 2013). Moreover, gelsolin binds 
and modulates the cellular effects of some 
bioactive lipids or inflammatory mediators 
such as lipopolysaccharide, lipoteichoic acid, 
lysophosphatidic acid, and platelet-activating 
factor (Osborn et al., 2007). In this study, it 
is observed that elevated total cholesterol 
may in turn reduce gelsolin expression. To 
date, the mechanism of gelsolin in lipid me-
tabolism and inflammation response remains 
unclear. Plausible explanation can be drawn 
that hypercholesterolemia causes the deposit 
of cholesterol in blood vessel walls and con-
sequently induces inflammation in the blood 
circulation (Libby et al., 2000). Supportive 
evidences on the decrease of gelsolin levels 
have been reported in acute injury and in-
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flammation such as ischemic stroke, rheuma-
toid arthritis, chronic kidney disease, and in-
fectious diseases (Peddada et al., 2012). 
Some study has suggested that gelsolin may 
prevent inflammation and reduce blood clot-
ting (Le et al., 2011). Moreover, gelsolin is 
also associated with apoptosis that acts as 
anti-apoptosis by inhibition of cascade activ-
ities. In the case of haptoglobin, it is a gly-
coprotein produced by liver and adipose tis-
sue. Therefore, the inflammation stated earli-
er led to the induction of cytokine release 
(e.g. IL-6 and IL-1β). These cytokines fur-
ther stimulate the hepatocytes to increase the 
synthesis of acute phase protein, in particu-
lar, haptoglobin and C-reactive proteins 
(Castell et al., 1989). Since it is reported that 
haptoglobin implicates in acute phase re-
sponse to inflammation in which the high 
levels of haptoglobin were found in several 
diseases that involve in cardiovascular dis-
ease and inflammation such as over-
weight/obesity, artherothombotic ischemic 
stroke, and myocardial infarction (Chiellini 
et al., 2004; De Pergola et al., 2007). Other 
studies suggested that high levels of choles-
terol were related with high inflammation 
sensitive plasma protein (ISP) including fi-
brinogen, haptoglobin, alpha1-antitrypsin, 
ceruloplasmin and orosomucoid (Engstrom 
et al., 2002). In addition, inflammation is a 
major role in the development of artheroscle-
rosis and cardiovascular diseases since it can 
reduce plaque stability and increase throm-
bogenesis that lead to CVD (Brea et al., 
2009; Engstrom et al., 2002). 
In summary, the molecular mechanisms 
of hypercholesterolemia-induced alterations 
of serum proteins were successfully explored 
by proteomics approach. Six proteins includ-
ing retinol-binding protein 4 (RBP4), trans-
thyretin (TTR), gelsolin, haptoglobin, com-
plement factor B (CFB) and CD5 antigen-
like protein (CD5L) were identified to play 
imperative roles in lipid metabolism and in-
flammatory processes as a consequence of 
hypercholesterolemia. Among these proteins, 
the RBP4 has been taken into accounts as a 
major linkage between hypercholesterole-
mia, adipose tissues, liver and kidney. 
Down-regulation of RBP4 expression or loss 
of RBP4 via the kidney clearance has been 
detected in all samples containing high blood 
cholesterol (> 240 mg/dL). Therefore, the 
RBP4 is believed to be a potential biomarker 
for metabolic and cardiovascular disorders 
associated with dyslipidemia in the near fu-
ture. 
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